Sight Sciences Announces Updated FDA Indications For TearCare, Effective August 18
UBS Maintains Buy on Sight Sciences, Raises Price Target to $8
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
Sight Sciences (NASDAQ:SGHT) Beats Q2 Estimates and Raises Guidance, but Shares Dip
Sight Sciences Raises FY2026 Sales Guidance from $83.000M-$89.000M to $88.000M-$92.000M vs $86.083M Est
Sight Sciences Q2 EPS $(0.08) Beats $(0.15) Estimate, Sales $23.388M Beat $21.682M Estimate
Sight Sciences Receives FDA 510(k) Clearance For OMNI Ultra Surgical System; Next-Generation Implant-Free MIGS Device For Primary Open-Angle Glaucoma
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $6
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $5.15
Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Sight Sciences Raises FY2026 Sales Guidance from $82.000M-$88.000M to $83.000M-$89.000M vs $84.695M Est
Sight Sciences Q1 EPS $(0.24) Misses $(0.18) Estimate, Sales $19.700M Beat $18.544M Estimate
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Sight Sciences To Present Data On Two Of Its Proprietary Glaucoma And Dry Eye Technologies, OMNI Surgical System And TearCare System, At 2026 ASCRS Annual Meeting
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
U.S. District Court Preserves Jury's Willful Infringement Verdict In Sight Sciences Case Vs Alcon
Citigroup Maintains Neutral on Sight Sciences, Lowers Price Target to $6.5
Sight Sciences, Inc. Q4 2025 Earnings Call Summary
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.